恶性血液病的肿瘤免疫逃逸(4)
[5] Dermime S， Mavroudis D， Jiang YZ， Hensel N， Molldrem J， Barrett AJ. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant， 1997， 19(10)：989-999.
[6] Anguille S， Van Tendeloo VF， Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia，2012，26(10)：2186-2196.
, 百拇医药
[7] Zheng Z， Takahashi M， Aoki S， Toba K， Liu A， Osman Y， Takahashi H， Tsukada N， Suzuki N， Nikkuni K， Furukawa T， Koike T， Aizawa Y. Expression patterns of costimulatory molecules on cells derived from human hematological malign-ancies. J Exp Clin Cancer Res，1998，17(3)：251-258.
[8] Menter T， Tzankov A. Mechanisms of immune evasion and immune modulation by lymphoma cells. Front Oncol，2018，8：54.
[9] Hirano N， Takahashi T， Takahashi T， Azuma M， Yazaki Y， Yagita H， Hirai H. Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells. Leukemia，1997，11 Suppl 3：577-581.
, 百拇医药
[10] Buggins AG， Lea N， Gaken J， Darling D， Farzaneh F， Mufti GJ， Hirst WJ. Effect of costimulation and the microenvironment on antigen presentation by leukemic cells. Blood，1999，94(10)：3479-3490.
[11] Chang X， Zang X， Xia CQ. New strategies of DLI in the mana-gement of relapse of hematological malignancies after allogeneic hematopoietic SCT. Bone Marrow Transplant，2016，51(3)：324-332.
[12] Sahin U， Dalva K， Gungor F， Ustun C， Beksac M. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation. Ann Hematol，2018，97(6)：1027-1039.
, http://www.100md.com
[13] Armand P. Immune checkpoint blockade in hematologic malign-ancies. Blood，2015，125(22)：3393-3400.
[14] 钱小庆， 张民杰. PD-1/PD-L1在脓毒症免疫中的作用. 新医学， 2017，48(10)：22-26.
[15] Gong J， Chehrazi-Raffle A， Reddi S， Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy： a comprehensive review of registration trials and future conside-rations. J Immunother Cancer，2018，6(1)：8.
[16] Park JH， Geyer MB， Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies： interpreting clinical outcomes to date. Blood，2016，127(26)：3312-3320.
(收稿日期：2019-04-02)
(本文編辑：洪悦民), 百拇医药(魏艳利 许莲蓉)
[6] Anguille S， Van Tendeloo VF， Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia，2012，26(10)：2186-2196.
, 百拇医药
[7] Zheng Z， Takahashi M， Aoki S， Toba K， Liu A， Osman Y， Takahashi H， Tsukada N， Suzuki N， Nikkuni K， Furukawa T， Koike T， Aizawa Y. Expression patterns of costimulatory molecules on cells derived from human hematological malign-ancies. J Exp Clin Cancer Res，1998，17(3)：251-258.
[8] Menter T， Tzankov A. Mechanisms of immune evasion and immune modulation by lymphoma cells. Front Oncol，2018，8：54.
[9] Hirano N， Takahashi T， Takahashi T， Azuma M， Yazaki Y， Yagita H， Hirai H. Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells. Leukemia，1997，11 Suppl 3：577-581.
, 百拇医药
[10] Buggins AG， Lea N， Gaken J， Darling D， Farzaneh F， Mufti GJ， Hirst WJ. Effect of costimulation and the microenvironment on antigen presentation by leukemic cells. Blood，1999，94(10)：3479-3490.
[11] Chang X， Zang X， Xia CQ. New strategies of DLI in the mana-gement of relapse of hematological malignancies after allogeneic hematopoietic SCT. Bone Marrow Transplant，2016，51(3)：324-332.
[12] Sahin U， Dalva K， Gungor F， Ustun C， Beksac M. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation. Ann Hematol，2018，97(6)：1027-1039.
, http://www.100md.com
[13] Armand P. Immune checkpoint blockade in hematologic malign-ancies. Blood，2015，125(22)：3393-3400.
[14] 钱小庆， 张民杰. PD-1/PD-L1在脓毒症免疫中的作用. 新医学， 2017，48(10)：22-26.
[15] Gong J， Chehrazi-Raffle A， Reddi S， Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy： a comprehensive review of registration trials and future conside-rations. J Immunother Cancer，2018，6(1)：8.
[16] Park JH， Geyer MB， Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies： interpreting clinical outcomes to date. Blood，2016，127(26)：3312-3320.
(收稿日期：2019-04-02)
(本文編辑：洪悦民), 百拇医药(魏艳利 许莲蓉)